MedinCell SA · EURONEXT:MEDCL
MedinCell SA — H1 FY2020 Earnings Presentation
12 slides from MedinCell SA's earnings presentation, December 2019
Slide 1: Half-year Financial results presentation
Audioconference Half-year Financial results presentation Closing September 30 2019
Slide 2: Agenda
Audioconference Agenda • Management presentation • Answers to shareholders' questions You can send your questions by using the chat on the right of your screen
Slide 3: Jaime Arango
Jaime Arango •
Slide 4: Financial highlights
Financial highlights • Cash & financial assets • 16,1 M€ cash & cash equivalent • 4,7 M€ risk-free • 7,5 M€ from EIB loan •
Slide 5: Revenue
Revenue • 3,9 M€ (+117%) •
Slide 6: Operating expenses
Operating expenses • 11,9 M€(+42%) • 75% of growth from product development •
Slide 7: Christophe Douat
Christophe Douat •
Slide 8: Portfolio
Portfolio • mdc-ANG Preclinical • mdc-TJK IND clearance for clinical • Animal Health Launch of activities • HIV Grant from Gates Foundation for exploratory program in HIV Prevention •
Slide 9: Post-closing events
Post-closing events • mdc-WWM Agreement up to 19 M$ with the Gates Foundation • mdc-TJK First in human started • mdc-IRM Interim analysis second half of 2020 •
Slide 10: Christophe Douat
Christophe Douat •
Slide 11: Q&A
Q&A You can send your questions by using the chat on the right of your screen
Slide 12: THANK YOU
THANK YOU MedinCell 3, rue des frères Lumière www.medincell.com 34830 Jacou • France